Allergen‐specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co‐inhibitory molecule, in allergic rhinitis

Abstract

These results suggest that both IL-5 production and down-regulation of BTLA in response to allergen are inhibited in SIT-treated patients with JCP. BTLA-mediated co-inhibition of IL-5 production may contribute to the regulation of allergen-specific T cell responses in patients receiving immunotherapy.